Neurocrine Biosciences, Inc. (NBIX) saw its loss widen to $44.66 million, or $0.51 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $29.32 million, or $0.34 a share.

The company has not recorded any revenues for the current quarter.

Operating loss for the quarter was $46.25 million, compared with an operating loss of $30.75 million in the previous year period.

"2016 was a very successful year for Neurocrine highlighted by the filing of our INGREZZA New Drug Application for tardive dyskinesia which was granted Priority Review by the FDA with a PDUFA date of April 11, 2017," said Kevin Gorman, Ph.D., chief executive officer of Neurocrine Biosciences. "2017 will truly be a pivotal year for Neurocrine; we have been preparing all aspects of the company for the anticipated commercial launch of INGREZZA in the United States. We also in-licensed the U.S. commercial rights to opicapone for Parkinson's disease, a novel COMT inhibitor recently approved in Europe. In addition, our partner AbbVie is planning to submit the NDA for elagolix in endometriosis during the third quarter of this year and is also anticipating top-line data from the pivotal studies of elagolix in uterine fibroids at year end. Our 2017 plans put us firmly on track to achieve our goal of building a multi-product, commercial-stage company with a robust and sustainable pipeline."

For fiscal year 2017, Neurocrine Biosciences, Inc. expects revenue to be $30 million.

Working capital declines

Neurocrine Biosciences, Inc. has witnessed a decline in the working capital over the last year. It stood at $280.03 million as at Dec. 31, 2016, down 21.86 percent or $78.33 million from $358.36 million on Dec. 31, 2015. Current ratio was at 10.21 as on Dec. 31, 2016, down from 14.94 on Dec. 31, 2015.